Brain, Vol. 125, No. 1, 75-85,
January 1, 2002
© 2002 Oxford University Press
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?
,2,31Institute for Neuropathology, Charité, Humboldt-University, Berlin, 2Institute for Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, 3Department of Neuroimmunology, Max-Planck-Institute for Neurobiology, Martinsried, Germany and 4Department of Neuroimmunology, Brain Research Institute, University of Vienna, Austria Correspondence to: Professor Dr Hans Lassmann, Brain Research Institute, Department of Neuroimmunology, Spitalgasse 4, A-1090 Vienna, Austria E-mail: hans.lassmann{at}univie.ac.at
*These authors contributed equally to this paper Present address: Brain Research Institute, University of Zurich, CH-8057 Zurich, Switzerland
Recent immunohistological and imaging studies emphasize the crucial role of axonal injury in determining the extent of permanent neurological deficits in patients with multiple sclerosis. We have recently shown that human immune cells are capable of producing the neurotrophin brain-derived neurotrophic factor (BDNF), which can prevent axonal and neuronal damage after various pathological insults. BDNF imported into the CNS by immune cells would thus be an attractive candidate for mediating neuroprotective effects in multiple sclerosis. The aim of the present study was to perform a detailed immunohistochemical analysis of the expression of BDNF and its receptor truncated trkB tyrosine kinase receptor (gp145trkB) in a series of multiple sclerosis brain lesions. Our data show that various types of neurones throughout the brain are BDNF immunopositive in multiple sclerosis patients as well as in controls. Furthermore, in multiple sclerosis lesions, BDNF is primarily present in immune cells (T cells, macrophages/microglia) and reactive astrocytes. The number of BDNF immunopositive cells correlates with lesional demyelinating activity. The BDNF receptor gp145trkB is found in neurones in the immediate vicinity of multiple sclerosis plaques as well as in reactive astrocytes within the lesion, but not in immune cells. Our results demonstrate that both BDNF and gp145trkB are expressed in multiple sclerosis lesions. This suggests that BDNF and gp145trkB are involved in immune-mediated neuroprotective interactions in multiple sclerosis, and supports the concept that immune cells produce both damaging and protective factors in multiple sclerosis lesions.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Wilkins and N Scolding Protecting axons in multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1013 - 1025. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Zivadinov, B. Weinstock-Guttman, R. Benedict, M. Tamano-Blanco, S. Hussein, N. Abdelrahman, J. Durfee, and M. Ramanathan Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor Hum. Mol. Genet., November 15, 2007; 16(22): 2659 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Feger, E. Tolosa, Y.-H. Huang, A. Waschbisch, T. Biedermann, A. Melms, and H. Wiendl HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation Blood, July 15, 2007; 110(2): 568 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hohlfeld, M. Kerschensteiner, and E. Meinl Dual role of inflammation in CNS disease Neurology, May 29, 2007; 68(22_suppl_3): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sarchielli, M. Zaffaroni, A. Floridi, L. Greco, A. Candeliere, A. Mattioni, S. Tenaglia, M. Di Filippo, and P. Calabresi Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-{beta} 1a, and high doses of immunoglobulins Multiple Sclerosis, April 1, 2007; 13(3): 313 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Jee, R. Liu, X.-F. Bai, D. I. Campagnolo, F.-D. Shi, and T. L. Vollmer Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int. Immunol., April 1, 2006; 18(4): 537 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aharoni, R. Eilam, H. Domev, G. Labunskay, M. Sela, and R. Arnon The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice PNAS, December 27, 2005; 102(52): 19045 - 19050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Liu, C. Stadelmann, M. Moscarello, W. Bruck, A. Sobel, F. G. Mastronardi, and P. Casaccia-Bonnefil Expression of Stathmin, a Developmentally Controlled Cytoskeleton-Regulating Molecule, in Demyelinating Disorders J. Neurosci., January 19, 2005; 25(3): 737 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Arnon and R. Aharoni Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications PNAS, October 5, 2004; 101(suppl_2): 14593 - 14598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld Immunologic factors in primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S16 - S22. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, June 1, 2004; 10(1_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
R. Hohlfeld Immunologic factors in primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S16 - S22. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, May 1, 2004; 10(3_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Sasaki, J. Hirabayashi, H. Manya, K.-i. Kasai, and T. Endo Galectin-1 induces astrocyte differentiation, which leads to production of brain-derived neurotrophic factor Glycobiology, April 1, 2004; 14(4): 357 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Burbach, R. Hellweg, C. A. Haas, D. Del Turco, U. Deicke, D. Abramowski, M. Jucker, M. Staufenbiel, and T. Deller Induction of Brain-Derived Neurotrophic Factor in Plaque-Associated Glial Cells of Aged APP23 Transgenic Mice J. Neurosci., March 10, 2004; 24(10): 2421 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Aharoni, B. Kayhan, R. Eilam, M. Sela, and R. Arnon Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ PNAS, November 25, 2003; 100(24): 14157 - 14162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gold and C. Linington Reply Brain, June 1, 2003; 126(6): E1 - E1. [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos and P. Duda The Janus face of CNS-directed autoimmune response: a therapeutic challenge Brain, November 1, 2002; 125(11): 2379 - 2380. [Full Text] [PDF]
|
|
|
|
|
|
T. Ziemssen, T. Kumpfel, W. E. F. Klinkert, O. Neuhaus, and R. Hohlfeld Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy Brain, November 1, 2002; 125(11): 2381 - 2391. [Abstract] [Full Text] [PDF]
|
|